Currently, the diagnosis of AD depends on the measurement of Aβ42, total tau, or p‐tau protein level in CSF, obtained via an invasive lumbar puncture, accompanied by neuroimaging techniques, such as positron emission tomography (PET) and magnetic resonance imaging (MRI) (Jack Jr. The gene discussed is MAPT; the disease is Alzheimer disease.